Frequency of Cardiac Complications in Thalassemia Major Patients
DOI:
https://doi.org/10.70749/ijbr.v3i4.976Keywords:
Beta-Thalassemia Major, Cardiac Complications, Cardiomegaly, Iron Overload, Serum FerritinAbstract
Background: Thalassemia major (TM) is a genetic hemoglobinopathy characterized by chronic anemia and iron overload due to frequent blood transfusions. Cardiac complications are a significant cause of morbidity and mortality in these patients, primarily due to iron accumulation in the heart. Early identification and management of these complications are essential to improve outcomes. Objectives: To assess the frequency and types of cardiac complications in children with beta-thalassemia major and to identify their association with age, gender, duration of transfusion, and serum ferritin levels. Study Settings: Department of Pediatrics, Allied Hospital Faisalabad. Duration of Study: 10th May 2024 to 9th November 2024. Data Collection: This cross-sectional study included 110 children aged 5–15 years with confirmed beta-thalassemia major, who had received at least five blood transfusions. Data collection involved clinical history, examination, serum ferritin levels, electrocardiography, and echocardiography to evaluate cardiac complications. Cardiac complications were categorized into cardiomegaly, congestive cardiac failure, cardiomyopathy, and pulmonary hypertension. Results: The frequency of cardiac complications was 60.45%, with cardiomegaly being the most common (51.85%), followed by congestive heart failure (24.69%), cardiomyopathy (14.81%), and pulmonary hypertension (8.64%). Cardiac complications were more frequent in patients with transfusion duration >5 years (64.49%, p=0.057) and serum ferritin ≤15 µg/ml (70.59%, p=0.162). However, age, gender, and serum ferritin levels were not significantly associated with cardiac complications. Conclusion: Cardiac complications are common in beta-thalassemia major patients, with cardiomegaly being the most frequent. Early screening and management of these complications are crucial to reduce morbidity and mortality in this high-risk population.
Downloads
References
Akiki N, Hodroj MH, Bou-Fakhredin R, Matli K, Taher AT. Cardiovascular Complications in β-Thalassemia: Getting to the Heart of It. Thalass. Rep. 2023, 13, 38–50. https://doi.org/10.3390/thalassrep13010005
Russo V, Melillo E, Papa AA, Rago A, Chamberland C, Nigro G. Arrhythmias and sudden cardiac death in beta-thalassemia major patients: noninvasive diagnostic tools and early markers. Cardiology Res Pract. 2019; 2019: e9319832. https://doi.org/10.1155/2019/9319832
John MJ, Jyani G, Jindal A, Mashon RS, Mathew A, Kakkar S, et al. Cost effectiveness of hematopoietic stem cell transplantation compared with transfusion chelation for treatment of thalasemia major. Biol Blood Marrow Transpl. 2018; 24(10): 2119–26. https://doi.org/10.1016/j.bbmt.2018.04.005
Mehmood R, Yaqoob U, Sarfaraz A, Zubair U. Complete blood picture with skeletal and visceral changes in patients with thalassemia major. Int J Health Sci (Qassim). 2018; 12(4):3-10.
Panda PK, Sharma Y. Ferritin level: Predictor of thalassemia cardiomyopathy. Heart India. 2018; 6(1):18-21. https://doi.org/10.4103/heartindia.heartindia_8_17
Salama KM, Khaled HZ, El Dien HMS, Afifi RARAA, Shaheen NMM, Abd el Wahab MAM. Assessment of Cardiac Functions and Arrhythmia in Children with Beta-Thalassemia Major and Beta-Thalassemia Intermedia. Open Access Maced J Med Sci. 2022; 10(B):890-5. https://doi.org/10.3889/oamjms.2022.9026
Hamid N, Shafique MF, Zaman QU, Niaz H. Frequency and Significance of Electrocardiographic Changes in Beta Thalassemia Major Patients. Pak Armed Forces Med J. 2022; 72(1): 136-40. https://doi.org/10.51253/pafmj.v72i1.3725
Khalid S, Saleem M, Anwer J, Iqbal R, Haq R, Ghafoor MB. Frequency of cardiac complications in beta thalassemia major patients at thalassemia center, Sheikh Zayed Hospital, Rahim Yar Khan. J. Sheikh Zayed Med. 2018;9(3): 1720-4.
Samira Z S, Basma A A, Abd El-Hakim A Abd El-Hakim ,Suzan M O, Amr S A. The early cardiac involvement in patients with b-thalassemia major. The Egyptian Heart Journal. 2013; 65: 243–9. https://doi.org/10.1016/j.ehj.2013.01.002
Borgna – Pignattic, Cappellini MD, DE Stegano P, Del Vecchio GC, Forni GL, Gamberini MR. Survival and complications in Thalassemia. Ann N Y Acad Sci. 2005;1054: 40-7. https://doi.org/10.1196/annals.1345.006
Khan F.UR, Amin J M M, Ayub T, Khan M H, Shah S H. Frequency of heart failure in patients with beta Thalassemia major. Gomel J Med Sci. July-Dec 2006;4(2):49-51.
Lekawanvijit S, Chattipakorn N. Iron overload Thalassemic cardiomyopathy. Iron status assessments and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol. 2009 April;25(4):213-18. https://doi.org/10.1016/s0828-282x(09)70064-9
Aessopos A, Farmakis D. Pulmonary hypertension in beta-thalassemia. Ann NYAcad Sci.2005; 1054:342-9. https://doi.org/10.1196/annals.1345.041
Adjimani JP, Asare P. Antioxidant and free radical scavenging activity of iron chelators. Toxicol. Rep. 2015;2:721–8. https://doi.org/10.1016/j.toxrep.2015.04.005
Kremastinos DT, Farmakis D, Aessopos A, Hahalis G, Hamodraka E, Tsiapras, D, et al. Beta-thalassemia cardiomyopathy: History, present considerations, and future perspectives. Circ. Heart Fail. 2010;3:451–458. https://doi.org/10.1161/circheartfailure.109.913863
Nomani H, Bayat G, Sahebkar A, Fazelifar AF, Vakilian F, Jomezade V, et al. Atrial fibrillation in β-thalassemia patients with a focus on the role of iron-overload and oxidative stress: A review. J. Cell. Physiol. 2019;234:12249–12266. https://doi.org/10.1002/jcp.27968
Advani N, Advani N, Andriastuti M. The corrected QT interval prolongation in adolescents with cardiac iron overload β-thalassemia major. Turk. J. Pediatr. 2020;62:267–273. https://doi.org/10.24953/turkjped.2020.02.013
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
